JP7126522B2 - （＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用 - Google Patents

（＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用 Download PDF

Info

Publication number
JP7126522B2
JP7126522B2 JP2019563863A JP2019563863A JP7126522B2 JP 7126522 B2 JP7126522 B2 JP 7126522B2 JP 2019563863 A JP2019563863 A JP 2019563863A JP 2019563863 A JP2019563863 A JP 2019563863A JP 7126522 B2 JP7126522 B2 JP 7126522B2
Authority
JP
Japan
Prior art keywords
formula
salt
disorders
compound
formula iib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520936A5 (enExample
JP2020520936A (ja
Inventor
クラス・ソーネソン
マイヤ・ブクサ
イネセ・レイネ
Original Assignee
インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー filed Critical インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー
Publication of JP2020520936A publication Critical patent/JP2020520936A/ja
Publication of JP2020520936A5 publication Critical patent/JP2020520936A5/ja
Application granted granted Critical
Publication of JP7126522B2 publication Critical patent/JP7126522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2019563863A 2017-05-19 2018-05-18 （＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用 Active JP7126522B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP17171938 2017-05-19
EP17171938.8 2017-05-19
EP17195451.4 2017-10-09
EP17195451 2017-10-09
EP17207406 2017-12-14
EP17207406.4 2017-12-14
EP18151428 2018-01-12
EP18151428.2 2018-01-12
PCT/EP2018/063123 WO2018211080A1 (en) 2017-05-19 2018-05-18 (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Publications (3)

Publication Number Publication Date
JP2020520936A JP2020520936A (ja) 2020-07-16
JP2020520936A5 JP2020520936A5 (enExample) 2021-04-08
JP7126522B2 true JP7126522B2 (ja) 2022-08-26

Family

ID=62599537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563863A Active JP7126522B2 (ja) 2017-05-19 2018-05-18 （＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用

Country Status (10)

Country Link
US (3) US11078158B2 (enExample)
EP (1) EP3625213B1 (enExample)
JP (1) JP7126522B2 (enExample)
CN (1) CN110621659B (enExample)
CA (1) CA3064136A1 (enExample)
DK (1) DK3625213T3 (enExample)
ES (1) ES2943252T3 (enExample)
FI (1) FI3625213T3 (enExample)
PL (1) PL3625213T3 (enExample)
WO (1) WO2018211080A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239568A1 (en) * 2019-05-24 2020-12-03 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
CA3180417A1 (en) * 2020-06-10 2021-12-16 Guillaume Dutheuil Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
WO2025003437A1 (en) 2023-06-28 2025-01-02 Integrative Research Laboratories Sweden Ab A pharmaceutical composition comprising a fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509861A (ja) 2008-11-24 2012-04-26 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
EP1582524B1 (en) 2004-04-02 2008-08-13 Ludwig Maximilians Universität Method of preparing organomagnesium compounds
CN101808987A (zh) * 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509861A (ja) 2008-11-24 2012-04-26 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BYRN S，PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS，PHARMACEUTICAL RESEARCH，米国，KLUWER ACADEMIC PUBLISHERS，1995年07月01日，V12 N7，P945-954
J. Pharm. Sci.，1975年，６４，３６７－３９１
Journal of High Technology Law，2009年，p.22-74
Journal of Pharmaceutical Sciences，1977年，Vol.66, No.1，p.1-19
Nature，2009年05月19日，４５８，２６９
PHARM TECH JAPAN，2002年，Vol.18, No.10，pp.1629-1644

Also Published As

Publication number Publication date
FI3625213T3 (fi) 2023-05-29
US12091384B2 (en) 2024-09-17
CA3064136A1 (en) 2018-11-22
ES2943252T3 (es) 2023-06-12
US20240400505A1 (en) 2024-12-05
CN110621659A (zh) 2019-12-27
JP2020520936A (ja) 2020-07-16
PL3625213T3 (pl) 2023-07-17
US20200024231A1 (en) 2020-01-23
CN110621659B (zh) 2023-02-28
DK3625213T3 (da) 2023-04-24
EP3625213A1 (en) 2020-03-25
EP3625213B1 (en) 2023-03-08
WO2018211080A1 (en) 2018-11-22
US11078158B2 (en) 2021-08-03
US20210317081A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US20240400505A1 (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
JP7623958B2 (ja) ［２－（３－フルオロ－５－メタンスルホニルフェノキシ）エチル］（プロピル）アミンの薬学的に許容される塩、およびその使用
US20230312573A1 (en) Novel salts, crystals, and co-crystals
US11566000B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
KR102768447B1 (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
EP1853576B1 (en) Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
HK40012481A (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
HK40012481B (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
KR102892833B1 (ko) [2-(3-플루오로-5-메탄-술포닐페녹시)에틸](프로필)아민의 제약상 허용되는 염 및 그의 용도
WO2025008504A1 (en) Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
HK40043660A (en) Novel method for preparing (-)-cibenzoline succinate
HK1050518A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220816

R150 Certificate of patent or registration of utility model

Ref document number: 7126522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250